Sustained API price weakness
API prices remain lower than last year despite recent uptick; further decline could delay turnaround and keep losses elevated.
AKUMSDRUGSPHARMACEUTICAL / Q4-FY26 / risks
Keep the risk register visible.
Akums Drugs & · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Execution risk in Zambia and European contracts
Delays in regulatory approvals or tech transfer could push back revenue recognition from these large contracts.
GLP-1 market entry uncertainty
Management was evasive on GLP-1 strategy, citing pricing volatility; missing this opportunity could limit future growth.
Working capital increase
Working capital days rose from 91 to 105 due to inventory buildup; further increases could pressure cash flows.